** Shares of drug developer Lipocine up 6.19% at $5.5 in premarket trading
** Administration of Oral brexanolone, co's drug for treating post-partum depression, was consistent with therapies effective in managing depression, anxiety, tremors, and seizures
**Oral brexanolone was well-tolerated in the Phase 1 study, with a safety profile consistent with previous clinical studies
** As of last close stock up 85.30% YTD
(Reporting by Khusbu Jena)
((Khusbu.Jena@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。